Coredio’s haemodynamic heart failure (HF) assessment software has obtained breakthrough device designation from the US Food and Drug Administration (FDA).

The California-based digital health company’s cardiac performance simulation engine (CPSE) is designed to provide clinicians with a means to assess HF patients once they have been discharged from the hospital, a period in which patients are often less connected to their care teams, which is widely viewed as the most vulnerable time following HF.

Research indicates that following an episode of decompensation, approximately 30% of patients hospitalised with HF are readmitted within three months of discharge, with mortality during this period approaching 10%.